For millions of Americans with obstructive sleep apnea, bedtime can feel less like rest and more like a nightly struggle with masks, hoses, and interrupted sleep. While CPAP machines remain the standard treatment, many patients abandon them because they find them uncomfortable, noisy, or difficult to use consistently. Now, a new sleep apnea pill called AD109 could change that conversation. If regulatory timelines stay on track, experts say the medication could potentially reach the market in 2027, offering a new option for an estimated 80 million Americans affected by sleep apnea.
